Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PROTHENA CORP PUBLIC LTD COPRTA · Entity 2375 | Chief Regulatory Officer | March 05, 2025 | March 07, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PROTHENA CORP PUBLIC LTD CO
Report date March 05, 2025 · Filed March 07, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.95 · Expires 2035-03-05 | Direct | 107,500 |
Reported balance
After 2025-03-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-03-05 · Grant · Acquired 107,500 · Balance 107,500 F1: The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on March 5, 2026, and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on March 5, 2026, and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 27, 2019 Filed Mar 1, 2019 16:15 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $13.53 | $0.00 |
DisclosureSEC source: 0000899243-19-005426 · doc4.xml · derivative · entry 1 Karp Carol D. · CIK 0001692214 · Chief Regulatory Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Ordinary Shares · 50,000 shares Expires 2029-02-27 F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on February 27, 2020 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| June 21, 2018 Filed Jun 25, 2018 16:31 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | GrantStock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $15.04 | $0.00 |
DisclosureSEC source: 0000899243-18-017933 · doc4.xml · derivative · entry 1 Karp Carol D. · CIK 0001692214 · Chief Regulatory Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Ordinary Shares · 150,000 shares Expires 2028-06-21 F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on June 21, 2019 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| February 21, 2018 Filed Feb 23, 2018 16:05 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | GrantStock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $33.10 | $0.00 |
DisclosureSEC source: 0000899243-18-005295 · doc4.xml · derivative · entry 1 Karp Carol D. · CIK 0001692214 · Chief Regulatory Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Ordinary Shares · 60,000 shares Expires 2028-02-21 F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on February 21, 2019 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| December 14, 2016 Filed Dec 16, 2016 16:11 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $52.78 | $0.00 |
DisclosureSEC source: 0000899243-16-035768 · doc4.xml · derivative · entry 1 Karp Carol D. · CIK 0001692214 · Chief Regulatory Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Ordinary Shares · 100,000 shares Expires 2026-12-14 F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on December 14, 2017 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.